Heghine Khachatryan: Advances in Targeted Therapy Transforming TTP Management at ASH Highlights 2026
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“ASH Highlights 2026 – Advances in Thrombotic Thrombocytopenic Purpura (TTP)
One of the most impactful sessions today focused on emerging therapeutic strategies in immune TTP (iTTP) and congenital TTP (cTTP), particularly CD38-targeted therapy and recombinant ADAMTS13 replacement.
Daratumumab in Immune TTP (iTTP)
Data from the international, multicenter DarTTP study demonstrated:
- Rapid ADAMTS13 remission in 75% of patients with iTTP who were refractory or intolerant to rituximab and other immunosuppressive therapies
- Sustained remission (>6 months) in approximately two-thirds of responders
- Targeting CD38+ plasma cells offers a promising strategy in cases where B-cell depletion alone is insufficient
These findings represent an important advancement in the management of refractory iTTP and provide renewed hope for patients at high risk of relapse.
Congenital TTP (cTTP)
The session also highlighted a clinical case discussion and phase 3 data on recombinant ADAMTS13 (rADAMTS13) replacement therapy:
- Demonstrated favorable efficacy and safety profile
- Approved in the US, EU, and Japan for both prophylactic and on-demand use
- Represents a paradigm shift in long-term cTTP management, reducing dependence on plasma infusions
This lecture clearly underscored that TTP treatment is entering a new era of mechanism-based and targeted therapy.
Integrating these advances into national practice remains crucial, particularly with regard to laboratory capacity, ADAMTS13 monitoring, and access to innovative therapeutics in our region.”
Find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Apr 1, 2026, 18:46Fritz Torto: Why Every Survivor Has a Duty to Build a Stronger Future for Others
-
Apr 1, 2026, 17:47Akshaya Sharon: Qfitlia as a Shift in Treatment Strategy for Hemophilia A and B
-
Apr 1, 2026, 17:21Antonio Pineda Guerrero: Elevated Lp(a) Raises VTE Risk But Only in the Right Hormonal Context
-
Apr 1, 2026, 17:19Shaik Nayeem Uddin: Clopidogrel and Omeprazole Combination Can Quietly Reduce A Life-Saving Effect
-
Apr 1, 2026, 17:18John Abraham: Breaking the ‘Bleeding Disorder’ Myth About Cirrhosis and Coagulation
-
Apr 1, 2026, 17:17Heghine Khachatryan: Linking Coagulation, Inflammation, and Neurodegeneration In Neuro-Hemostasis Axis
-
Apr 1, 2026, 17:15Chokri Ben Lamine: Differentiating Reactive from Clonal Causes in Adult Neutrophilia
-
Apr 1, 2026, 16:05Gregory Piazza: Discussing the 2026 AHA/ACC Guidelines for Acute PE at ACC.26
-
Apr 1, 2026, 15:31Simon Senanu: A Stepwise Laboratory Approach for aPTT Prolongation